Kaleido Biosciences Inc (KLDO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Alison Lawton
Employees:
18 CROSBY DRIVE, BEDFORD, MA 01730
617-674-9000

Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. Kaleido BioSciences, Inc. has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; and a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 12.352 Million Shares Outstanding42.594 Million Avg 30-day Volume 15.094 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.14
Price to Revenue92.2717 Debt to Equity2.0453 EBITDA-84.749 Million
Price to Book Value9.6038 Operating Margin-7940.8514 Enterprise Value85.088 Million
Current Ratio1.426 EPS Growth0.115 Quick Ratio1.296
1 Yr BETA 1.7967 52-week High/Low 9.47 / 0.15 Profit Margin-8178.2609
Operating Cash Flow Growth-25.3194 Altman Z-Score-14.0865 Free Cash Flow to Firm -59.911 Million
View SEC Filings from KLDO instead.

View recent insider trading info

Funds Holding KLDO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KLDO BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-04-08:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-11-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-05:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-03:
    Item 8.01: Other Events
  • 8-K: filed on 2021-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-06-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    KORN JERALD COO & GENERAL COUNSEL

    • Officer
    4,517 2022-02-28 3

    VAN HYLCKAMA VLIEG JOHAN CHIEF SCIENTIFIC OFFICER

    • Officer
    4,620 2022-02-28 3

    MENICHELLA DANIEL L CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    320,200 2022-01-14 2

    DUKE WILLIAM E. CHIEF FINANCIAL OFFICER

    • Officer
    169,990 2022-01-14 2

    LONG ALISON S CHIEF MEDICAL OFFICER

    • Officer
    171,800 2022-01-14 3

    MELAS KYRIAZI THEO

    • Director
    15,000 2021-06-30 1

    BONNEY MICHAEL W

    • Director
    30,000 2021-06-30 1

    QUINN ANTHONY G.

    • Director
    15,000 2021-06-30 1

    MIXER JEAN K

    • Director
    15,000 2021-06-30 1

    BASSLER BONNIE L

    • Director
    15,000 2021-06-30 1

    BURNETT GRADY

    • Director
    15,000 2021-06-30 1

    VON MALTZAHN GEOFFREY

    • Director
    15,000 2021-06-30 1

    PRENER ANNE

    • Director
    15,000 2021-06-30 1

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLC

    FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.

    NUTRITIONAL HEALTH LTP FUND GENERAL PARTNER LLC

    NUTRITIONAL HEALTH LTP FUND, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    19,575,710 2021-02-08 0

    KNOBIL KATHARINE CHIEF MEDICAL OFFICER

    • Officer
    0 2020-10-15 0

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLC

    FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    19,360,710 2020-06-04 0

    NUTRITIONAL HEALTH LTP FUND GENERAL PARTNER LLC

    NUTRITIONAL HEALTH LTP FUND, L.P.

    • 10% Owner
    666,666 2020-06-04 0

    LAWTON ALISON FRANCES SEE REMARKS

    • Officer
    • Director
    0 2020-04-15 0

    SCALZO RICHARD WILLIAM PRINCIPAL ACCOUNTING OFFICER

    • Officer
    0 2019-10-11 0

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP VENTURELABS V LLC

    FLAGSHIP VENTURELABS V MANAGER LLC

    FLAGSHIP PIONEERING INC.

    NUTRITIONAL HEALTH DISRUPTIVE INNOVATION FUND, L.P.

    NUTRITIONAL HEALTH SIDE FUND, L.P.

    FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.

    FLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLC

    AFEYAN NOUBAR

    • Director
    • 10% Owner
    14,504,284 2019-03-04 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 22:15:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 21:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 21:15:04 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 20:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 20:15:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 19:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 19:15:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 18:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 18:15:04 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 17:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 17:15:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 16:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 16:15:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 15:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 15:15:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 14:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 14:15:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 13:45:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 13:15:03 UTC -22.3235 23.8935 400000
    KALEIDO BIOSCIENCES INC KLDO 2022-06-24 12:45:03 UTC -22.3235 23.8935 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments